Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market
FDA Issues Clearance for ReWalk 7 Exoskeleton
ReWalk Robotics Ltd. (NASDAQ: LFWD) had its price target lowered by analysts at Lake Street Capital from $4.50 to $4.00. They now have a "buy" rating on the stock.
ReWalk Robotics Ltd. (NASDAQ: LFWD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results